BJMO - volume 18, issue 8, december 2024
P. Vanclooster MD
While ESMO 2024 once again did not yield a phase III trial for brain tumours, it presented intriguing findings from early-phase clinical trials and translational studies. We highlight three of the most significant and promising trials related to brain tumours discussed at the conference, particularly focusing on IDH-mutated tumours, glioblastoma, and novel immunotherapy strategies.
(BELG J MED ONCOL 2024;18(8):337–340)
Read moreBJMO - volume 18, issue 8, december 2024
B. Neyns MD, PhD
The treatment landscape of melanoma is very dynamic, with several clinical trials investigating novel treatment options for patients. Here, an overview of recent clinical trial data as well as melanoma survivor care are discussed.
(BELG J MED ONCOL 2024;18(8):332–336)
Read moreBJMO - volume 18, issue 8, december 2024
J. Kerger MD, M. Langouo Fontsa MD, G. El Hachem MD
ESMO 2024 again yielded a wealth of information regarding gynaecological cancers. Here, the key findings of the latest clinical trials in this field are discussed.
(BELG J MED ONCOL 2024;18(8):325–331)
Read moreBJMO - volume 18, issue 8, december 2024
W. Lybaert MD
The ESMO congress was held from 13–17th of September 2024, in a live and virtual format. During this congress, the promising combination of eftilagimod alpha and pembrolizumab as a chemotherapy-sparing regimen in first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) shows puzzling, but rather disappointing results at first analysis. Since adjuvant atezolizumab after concomitant chemoradiotherapy failed to improve results in locally advanced HNSCC, all eyes are now on the phase III JADE study in the same setting with dostarlimab. Neoadjuvant chemotherapy is an effective intervention that could improve organ preservation in patients with T3 and T4a nasal and paranasal sinus squamous cell carcinoma. Chemotherapy and androgen deprivation therapy (ADT) present equivalent results in androgen receptor (AR)-expressing salivary gland tumours, and trastuzumab deruxtecan enters as an efficacious new treatment line in this rare tumour type. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2024;18(8):317–324)
Read moreBJMO - volume 18, issue 8, december 2024
J. Dekervel MD, PhD
In September of 2024, the yearly ESMO congress took place in Barcelona. In this article, new insights that were presented in the field of gastrointestinal oncology are covered, with emphasis on the practice-changing or practice-informing new data.
(BELG J MED ONCOL 2024;18(8):311–316)
Read moreBJMO - volume 18, issue 8, december 2024
L. Decoster MD, PhD
ESMO 2024 did not bring any practice changing results in the field of lung cancer treatment. Nevertheless, interesting updates from previous trials and early phase trials could impact treatment options in the future.
(BELG J MED ONCOL 2024;18(8):308–310)
Read moreBJMO - volume 18, issue 8, december 2024
C. Vulsteke MD, PhD, K. Decaestecker PhD
Exciting developments in the clinical landscape of genitourinary cancers are forthcoming. This article provides an up-to-date overview of the recent trials across a wide range of genitourinary cancers.
(BELG J MED ONCOL 2024;1(8):303–307)
Read more
Top
